natgillin/translations-raw huggingface dataset:
Eksacerbationer af hjertelidelser som angina pectoris, kongestiv hjertesygdom eller alvorlige kardielle sygdomme (hjerteinsufficiens, myokardieinfarkt og atrieflimren), lungeødem, multiorgansvigt, tumorlysesyndrom, cytokinfrigivelsessyndrom, nyresvigt og respirationssvigt blev rapporteret med lavere eller ukendt hyppighed.
Exacerbations of pre-existing cardiac conditions such as angina pectoris or congestive heart failure or severe cardiac disorders (heart failure, myocardial infarction, atrial fibrillation), pulmonary oedema, multi-organ failure, tumour lysis syndrome, cytokine release syndrome, renal failure, and respiratory failure were reported at lower or unknown frequencies.
Farmakokinetikken for rituximab blev vurderet efter to i.v.-doser på 500 mg og 1.000 mg på dag 1 og 15 i fire studier.
The pharmacokinetics of rituximab were assessed following two intravenous (IV) doses of 500 mg and 1000 mg on Days 1 and 15 in four studies.
Rituximab blev givet på den første dag i en behandlingsserie.
Rituximab was administered on the first day of the treatment cycle.
R-CVP var signifikant bedre end CVP mht. det primære endepunkt, tid til behandlingssvigt (27 måneder versus 6,6 måneder), p < 0,0001,log rank test).
R-CVP led to a significant benefit over CVP for the primary endpoint, time to treatment failure (27 months vs. 6.6 months, p < 0.0001, log-rank test).
CTC og af IRR, som førte til seponering, faldt med antal behandlingsserier og var sjældne fra 3. behandlingsserie og frem.
The proportion of CTC Grade 3 events, and of IRRs leading to withdrawal decreased by course and were rare from course 3 onwards.
Der er observeret progression af Kaposis sarkom hos rituximabeksponerede patienter med Kaposis sarkom.
Progression of Kaposi's sarcoma has been observed in rituximab-exposed patients with preexisting Kaposi's sarcoma.
Hjælpestoffer: Dette lægemiddel indeholder 2,3 mmol (eller 52,6 mg) natrium pr. 10 ml hætteglas.
Excipients: This medicinal product contains 2.3 mmol (or 52.6 mg) sodium per 10 mL vial.
De fleste infusionsrelaterede hændelser rapporteret i kliniske studier med patienter med reumatoid artrit var lette til moderate i sværhedsgrad.
In rheumatoid arthritis most infusion-related events reported in clinical trials were mild to moderate in severity.
Hætteglas, af klart type I glas med butylgummiprop, indeholdende 500 mg rituximab i 50 ml.
Clear Type I glass vials with butyl rubber stopper containing 500 mg of rituximab in 50 mL.
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter): D. infektioner som f.eks. herpesudbrud og øjeninfektion E. humørsvingninger såsom irritabilitet og depression F. hudsygdomme såsom kløe, nældefeber og godartede knuder G. træthed og svimmelhed
Common side effects (may affect up to 1 in 10 people): infections such as herpes infections and eye infection mood disorders such as irritability and depression skin disorders such as itching, hives, and benign lumps feeling tired or dizzy fever headache pain in the tummy pain in the muscles heart beating faster than normal
Hændelsesfri overlevelse Responsrate (CR, nPR eller PR) CR-rater n.a. n.a.
Event free survival Response rate (CR, nPR, or PR) CR rates
Alopeci Pruritus Urticaria Hudsygdom
Alopecia Pruritus Urticaria Skin disorder
Biotec House, Central Park, Western Avenue Bridgend Industrial Estate Bridgend, CF31 3RT, Storbritannien og
Biotec Services International Ltd. Biotec House, Central Park, Western Avenue Bridgend Industrial Estate Bridgend, CF31 3RT, UK And
Sekondært effektmål
Secondary efficacy
Diffust storcellet B-celle non-Hodgkin-lymfom
Diffuse large B cell non-Hodgkin's lymphoma
Dette lægemiddel indeholder 263,2 mg natrium pr. 50 mL hætteglas, svarende til 13,2% af den WHO anbefalede maximale daglige indtagelse af 2 g natrium for en voksen.
This medicinal product contains 263.2 mg sodium per 50 mL vial, equivalent to 13.2% of the WHO recommended maximum daily intake of 2 g sodium for an adult.For the full list of excipients, see section 6.1.
Efter markedsføring har neutropeniske hændelser, herunder svær sent indsættende og vedvarende neutropeni, sjældent været rapporteret.
Neutropenic events, including severe late onset and persistent neutropenia, have been rarely reported in the post-marketing setting, some of which were associated with fatal infections.
• spiseforstyrrelser, for lille fødeindtagelse, der medfører vægttab
• eating disorders, not eating enough, leading to weight loss
Ved CLL var incidensen af hjertesygdomme af grad 3 eller 4 lav både i 1. linjestudiet (4 % R-FC, 3 % FC) og i relaps/refraktær studiet (4 % R-FC, 4 % FC).
In CLL, the overall incidence of grade 3 or 4 cardiac disorders was low both in the first-line study (4% R-FC, 3% FC) and in the relapsed/refractory study (4% R-FC, 4% FC).
Vedligeholdelsesbehandling vil gives 1 år og 18 måneder efter behandlingens start og herefter hver 6. måned efter behov.
This will be administered 1 year and 18 months after the initial treatment and then every 6 months as needed or your doctor may change this, depending on how you respond to the medicine.
Der er i meget sjældne tilfælde blevet rapporteret om tilfælde af progressiv multifokal leukoencefalopati (PML) efter markedsføring af rituximab hos patienter med NHL og CLL (se pkt.
Very rare cases of progressive multifocal leukoencephalopathy (PML) have been reported during post-marketing use of rituximab in NHL and CLL (see section 4.8).
Efter den femte 500 mg/m2 infusion var den gennemsnitlige Cmax (N = 15) 408 µg/ml (spændvidde 97-764 µg/ml), og den gennemsnitlige terminale halveringstid var 32 dage (spændvidde 14-62 dage).
The mean Cmax (N=15) was 408 µg/mL (range, 97 - 764 µg/mL) after the fifth 500 mg/ m2 infusion and the mean terminal half-life was 32 days (range, 14 - 62 days).
I skal fortsætte med sikker prævention i 12 måneder efter din sidste behandling med Ritemvia.
You must also do this for 12 months after your last treatment with Ritemvia.
Dette lægemiddel indeholder 52,6 mg natrium pr. 10 mL hætteglas, svarende til 2,6% af den WHO anbefalede maximale daglige indtagelse af 2 g natrium for en voksen.
This medicinal product contains 52.6 mg sodium per 10 mL vial, equivalent to 2.6% of the WHO recommended maximum daily intake of 2 g sodium for an adult.For the full list of excipients, see section 6.1.
Influenzalignende symptomer Perifert ødem
Influenza-like illness Oedema peripheral
+venstre ventrikulært svigt, +supraventrikulær takykardi, +ventrikulær takykardi, +angina, +myokardieiskæmi, bradykardi,
tachycardia, +cardiac disorder tachycardia, +ventricular tachycardia, +angina, +myocardial ischaemia, bradycardia
Størstedelen af patienterne (81 %) viste tegn på B-celleregenerering med > 10 celler/mikroliter ved måned 12; dette steg til 87 % af patienterne ved måned 18.
cell return, with counts > 10 cells/μL by month 12, increasing to 87% of patients by month 18.
Tegn på gendannelse af B-celler blev observeret hos størstedelen af patienterne ved uge 40, uanset om rituximab blev anvendt som monoterapi eller i kombination med methotrexat.
Peripheral blood B cell counts begin to increase from week 24 and evidence for repopulation is observed in the majority of patients by week 40, whether rituximab was administered as monotherapy or in combination with methotrexate.
Reaktionerne var karakteriseret ved pulmonale hændelser og omfattede i nogle tilfælde hurtig tumorlyse og tegn på tumorlysesyndrom foruden feber, kulderystelser, rigor, hypotension, urticaria, angioødem og andre symptomer (se pkt.
They were characterised by pulmonary events and in some cases included rapid tumour lysis and features of tumour lysis syndrome in addition to fever, chills, rigors, hypotension, urticaria, angioedema and other symptoms (see section 4.8).
I det kliniske studie med induktion af remission, som inkluderede 99 rituximab-behandlede patienter var den samlede infektionshyppighed ca. 237 pr. 100 patientår (95 % konfidensinterval 197-285) ved det primære endepunkt ved måned 6.
In the clinical trial on induction of remission, which included 99 rituximab-treated patients, the overall rate of infection was approximately 237 per 100 patient years (95% CI 197-285) at the 6month primary endpoint.
Derudover er der rapporteret om andre alvorlige virusinfektioner under behandling med rituximab, enten nye, reaktiverede eller recidiverede.
In addition, other serious viral infections either new, reactivated or exacerbated, some of which were fatal, have been reported with rituximab treatment.
Efter rekonstituering af immunsystemet hos immunkomprimerede patienter med PML er der set stabilisering eller forbedret tilstand.
Following reconstitution of the immune system in immunocompromised patients with PML,
Rituximabs binding til CD20 antigenet på B-lymfocytter har vist også at inducere celledød via apoptose.
Rituximab binding to CD20 antigen on B lymphocytes has also been demonstrated to induce cell death via apoptosis.
Læger bør udvise forsigtighed, når de overvejer brugen af rituximab til patienter, der tidligere har haft recidiverende eller kroniske infektioner eller patienter med tilgrundliggende forhold, der yderligere kan prædisponere dem til alvorlig infektion (se pkt.
Physicians should exercise caution when considering the use of rituximab in patients with a history of recurring or chronic infections or with underlying conditions which may further predispose patients to serious infection (see section 4.8).
Psykiske forstyrrelser depression, nervøsitet
Psychiatric disorders depression, nervousness,
Responsraterne var sammenlignelige ved vaccination med tetanus recall antigen (39 % versus 42 %), der var reduceret respons over for pneumokok polysaccharid vaccine (43 % versus 82 % over for mindst to pneumokokantistof serotyper) og over for KLH neoantigen (47 % versus 93 %), når vaccinationen blev givet 6 måneder efter rituximab-behandling.
In a randomised trial, patients with rheumatoid arthritis treated with rituximab and methotrexate had comparable response rates to tetanus recall antigen (39% vs. 42%), reduced rates to pneumococcal polysaccharide vaccine (43% vs. 82% to at least 2 pneumococcal antibody serotypes), and KLH neoantigen (47% vs. 93%), when given 6 months after rituximab as compared to patients only receiving methotrexate.
Det er vigtigt, fordi Ritemvia i enkelte tilfælde har forårsaget, at en tidligere leverbetændelse (hepatitis B) er blevet aktiv igen.
This is because in a few cases, Ritemvia could cause hepatitis B to become active again, which can be fatal in very rare cases.
Klinisk erfaring ved pemfigus vulgaris
Clinical experience in pemphigus vulgaris
Sikkerhedsprofilen for rituximab i kombination med kortvarig lavdosis glukokortikoider til behandling af patienter med PV blev undersøgt i et randomiseret, kontrolleret, åbent, multicenter fase III-studie, der inkluderede 38 patienter med PV randomiseret til rituximab-gruppen.
The safety profile of rituximab in combination with short-term, low-dose glucocorticoids in the treatment of patients with pemphigus vulgaris was studied in a Phase 3, randomised, controlled, multicenter, open-label study in pemphigus patients that included 38 pemphigus vulgaris (PV) patients randomised to the rituximab group.
Nervesystemet paræstesi, hypoæstesi, agitation, insomni, vasodilatation, svimmelhed, angst dysgeusi perifer neuropati facialisparese5
Nervous system disorders paraesthesia, hypoaesthesia, agitation, insomnia, vasodilatation, dizziness, anxiety dysgeusia peripheral neuropathy, facial nerve palsy5
Hætteglas, af klart type I glas med butylgummiprop, indeholdende 100 mg rituximab i 10 ml.
Clear Type I glass vials with butyl rubber stopper containing 100 mg of rituximab in 10 mL.
• Tidligere ubehandlet follikulært lymfom
• Previously untreated follicular lymphoma
Infusionsrelaterede reaktioner i det kliniske studie, hvor man så på induktion af remission hos patienter med svær, aktiv GPA eller MPA blev defineret som enhver bivirkning, der opstod inden for 24 timer efter en infusion i sikkerhedspopulationen, og som af investigator blev anset som værende infusionsrelateret.
Infusion-related reactions In the clinical trial studying induction of remission with severe active GPA and MPA, IRRs were defined as any adverse event occurring within 24 hours of an infusion and considered to be infusion-related by investigators in the safety population.
I begge arme fik patienterne intravenøs pulsbehandling med 1000 mg methylprednisolon (eller andet glukokortikoid i ækvivalent dosis) pr. dag i 1-3 dage efterfulgt af oral prednison (1 mg/kg/dag, dog højst 80 mg/dag).
Patients in both arms received 1000 mg of pulse intravenous (IV) methylprednisolone (or another equivalent-dose glucocorticoid) per day for 1 to 3 days, followed by oral prednisone (1 mg/kg/day, not exceeding 80 mg/day).
Frekvenserne er defineret som meget almindelig (≥ 1/10), almindelig (≥ 1/100 til < 1/10), ikke almindelig (≥ 1/1.000 til ≤ 1/100) og meget sjælden (< 1/10.000).
Frequencies are defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100) and very rare (< 1/10,000).
Dette syndrom kan ligne kliniske fund på tumorlyse syndrom som hyperuricæmi, hyperkaliæmi, hypocalcæmi, hyperphosphatæmi, akut nyresvigt, forhøjet laktatdehydrogenase (LD) og kan medføre akut respirationssvigt og død.
This syndrome may be associated with some features of tumour lysis syndrome such as hyperuricaemia, hyperkalaemia, hypocalcaemia, hyperphosphataemia, acute renal failure, elevated lactate dehydrogenase (LDH) and may be associated with acute respiratory failure and death.
Du vil som regel få en indsprøjtning med binyrebarkhormon, inden behandlingen med Ritemvia påbegyndes.
Corticosteroids will usually be given by injection before the start of Ritemvia treatment.
Non-Hodgkin-lymfom (NHL)
Non-Hodgkin's lymphoma (NHL)
Da der er begrænset viden om brug af Ritemvia til børn og unge, skal du kontakte lægen, apotekspersonalet eller sundhedspersonalet inden medicinen gives, hvis du eller dit barn er under 18 år.
Talk to your doctor, pharmacist or nurse before you are given this medicine if you, or your child, are under 18 years of age.
De to behandlingsgrupper var godt afbalanceret i forhold til baseline karakteristik og sygdomsstatus.
The two treatment groups were well balanced with regard to baseline characteristics and disease status.
I PV-populationen havde 5 (13 %) patienter i rituximab-gruppen og 3 (8 %) patienter i standarddosis prednison-gruppen moderat sygdom, og 33 (87 %) patienter i rituximabgruppen og 33 (92 %) patienter i standarddosis prednison-gruppen havde svær sygdom i henhold til sygdomssværhedsgrad defineret ved Harman's kriterier.
In the PV population, 5 (13%) patients in the rituximab group and 3 (8%) patients in the standard prednisone group had moderate disease and 33 (87%) patients in the rituximab group and 33 (92%) patients in the standard-dose prednisone group had severe disease according to disease severity defined by Harman's criteria.
Progressiv multifokal leukoencefalopati
Progressive multifocal leukoencephalopathy (PML)
Psykiske forstyrrelser depression, angst
Psychiatric disorders depression, anxiety
alvorlig virusinfektion2 pneumocystis jiroveci progressiv multifokal leukoencefalo pati
serious viral infection2 pneumocystis jirovecii
Gentagne behandlingsserier med rituximab i kombination med methotrexat resulterede i vedvarende forbedringer af kliniske symptomer på RA angivet ved ACR-DAS28-ESR-og EULAR-respons.
Treatment with rituximab in combination with methotrexate over multiple courses resulted in sustained improvements in the clinical signs and symptoms of RA, as indicated by ACR, DAS28ESR and EULAR responses which was evident in all patient populations studied (Figure 2).
Erfaringer med reumatoid artrit
Experience from rheumatoid arthritis
Der er meget sjældent blevet rapporteret om reaktivering af hepatitis B-infektion hos RA-patienter, som får rituximab (se pkt.
Reactivation of hepatitis B infection has also been very rarely reported in rheumatoid arthritis patients receiving rituximab (see section 4.4).
Nervesystemet hovedpine paræstesi, migræne, svimmelhed, iskias
Nervous system disorders headache paraesthesia, migraine, dizziness, sciatica
Til intravenøs anvendelse efter fortynding
For intravenous use after dilution
Andre symptomer omfattede hedeture, angioødem, bronkospasmer, opkastning, kvalme, urticaria/nældefeber, træthed, hovedpine, halsirritation, rhinitis, pruritus, smerter, takykardi, hypertension, hypotension, dyspnø, dyspepsi, asteni og tegn på tumorlysesyndrom.
Other symptoms included flushing, angioedema, bronchospasm, vomiting, nausea, urticaria/rash, fatigue, headache, throat irritation, rhinitis, pruritus, pain, tachycardia, hypertension, hypotension, dyspnoea, dyspepsia, asthenia and features of tumour lysis syndrome.
I det kliniske studie med induktion af remission havde henholdsvis 27 %, 58 % og 51 % af patienterne i rituximab-gruppen med normale immunglobulin-niveauer ved baseline lave IgA-, IgG- og IgMniveauer ved måned 6 sammenlignet med henholdsvis 25 %, 50 % og 46 % i cyclophosphamidgruppen.
In the induction of remission clinical trial, at 6 months, in the rituximab group, 27%, 58% and 51% of patients with normal immunoglobulin levels at baseline had low IgA, IgG and IgM levels, respectively, compared to 25%, 50% and 46% in the cyclophosphamide group.
Kardiale hændelser (herunder atrieflimren, myokardieinfarkt, venstre ventrikulært svigt og myokardieiskæmi) blev rapporteret som alvorlige bivirkninger hos 3 % af patienterne, som fik rituximab sammenlignet med < 1 % i observationsgruppen.
Cardiac events were reported as serious adverse events (including atrial fibrillation, myocardial infarction, left ventricular failure, myocardial ischaemia) in 3% of patients treated with rituximab compared to <1% on observation.
Hyppigheden af bivirkninger, uanset sværhedsgrad, var ens i de to grupper.
The incidence of ADRs of any grade was similar in these two groups.
Disse symptomer er sædvanligvis reversible, når rituximab-infusionen afbrydes, og der administreres et antipyretikum, et antihistamin og undertiden oxygen, intravenøst saltvand eller bronchodilaterende midler og glukokortikoider om nødvendigt.
These symptoms are usually reversible with interruption of rituximab infusion and administration of an anti-pyretic, an antihistaminic, and, occasionally, oxygen, intravenous saline or bronchodilators, and glucocorticoids if required.
Udmattelse Pyreksi
Fatigue Pyrexia
De rapporterede reaktioner var som regel reversible efter reduktion af hastigheden eller afbrydelse af rituximab-infusionen og administration af et antipyretikum, et antihistamin og lejlighedsvis oxygen, intravenøs saltvandsopløsning eller bronkodilatorer samt glukokortikoider, hvis det var påkrævet.
The reactions reported were usually reversible with a reduction in rate, or interruption, of rituximab infusion and administration of an anti-pyretic, an antihistamine, and, occasionally, oxygen, intravenous saline or bronchodilators, and glucocorticoids if required.
GLSG'00 CHOP, 205 R-CHOP, 223 18
CHOP, 205 R-CHOP,
Alle patienter behandlet med rituximab for reumatoid artrit, GPA, MPA eller PV skal have udleveret patientkortet ved hver infusion.
All patients treated with rituximab for rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris must be given the patient alert card with each infusion.
De mest almindelige symptomer på infusionsrelaterede reaktioner inkluderede hovedpine, kulderystelser, forhøjet blodtryk, kvalme, asteni og smerte.
The most common infusion-related reaction symptoms/Preferred Terms included headaches, chills, high blood pressure, nausea, asthenia and pain.
Tidligere ubehandlet follikulært lymfom
Previously untreated follicular lymphoma
De patienter, der blev randomiseret til rituximab-gruppen, fik en initial dosis på 1.000 mg intravenøst på studiedag 1 og endnu en dosis på 1.000 mg intravenøst på studiedag 15.
Patients randomised to the rituximab group received an initial 1000 mg IV on Study Day 1 and a second 1000 mg IV on Study Day 15.
Kardiovaskulære bivirkninger i kliniske studier med rituximab monoterapi blev rapporteret hos 18,8 % af patienterne.
Cardiovascular reactions during clinical trials with rituximab monotherapy were reported in 18.8% of patients with the most frequently reported events being hypotension and hypertension.
Angina pectoris, hjertearytmier såsom atrieflimren og atrieflagren, hjerteinsufficiens og/eller myokardieinfarkt er forekommet hos patienter behandlet med rituximab.
Angina pectoris, cardiac arrhythmias such as atrial flutter and fibrillation, heart failure and/or myocardial infarction have occurred in patients treated with rituximab.
Tabel 11 Behandling af relapsed/refraktær kronisk lymfatisk leukæmi - sammenfatning af resultaterne for effekt for rituximab plus FC versus FC alene (median observationstid: 25,3 måneder) Effektparameter
Table 11 Treatment of relapsed/refractory chronic lymphocytic leukaemia - overview of efficacy results for rituximab plus FC vs. FC alone (25.3 months median observation time) Efficacy Parameter
Erfaring fra pemfigus vulgaris
Experience from pemphigus vulgaris
Hvis du har granulomatose med polyangiitis, mikroskopisk polyangiitis fortæl da også din læge eller pemfigus vulgaris
If you have granulomatosis with polyangiitis, microscopic polyangiitis or pemphigus vulgaris also tell your doctor
42-måneder p = 0,029
42-months p = 0.029
Ritemvia kan anvendes alene eller sammen med kemoterapi.
Ritemvia can be given alone or with other medicines called “chemotherapy”.
Koncentrat til infusionsvæske, opløsning 500 mg/50 ml 1 hætteglas
Concentrate for solution for infusion 500 mg / 50 mL
Til den tid og inden for højst 1 måned efter den sidste cyclophosphamid pulsbehandling blev patienterne randomiseret til at få enten rituximab (to 500 mg intravenøse infusioner med to ugers mellemrum (på dag 1 og dag 15) efterfulgt af 500 mg intravenøst hver 6. måned i 18 måneder) eller azathioprin (administreret oralt i en dosis på 2 mg/kg/dag i 12 måneder, derefter 1,5 mg/kg/dag i 6 måneder og til sidst 1 mg/kg/dag i 4 måneder (behandlingsophør efter disse 22 måneder)).
At that time, and within a maximum of 1 month after the last cyclophosphamide pulse, patients were randomly assigned to receive either rituximab (two 500 mg IV infusions separated by two weeks (on Day 1 and Day 15) followed by 500 mg IV every 6 months for 18 months) or azathioprine (administered orally at a dose of 2 mg/kg/day for 12 months, then 1.5 mg/kg/day for 6 months, and finally 1 mg/kg/day for 4 months (treatment discontinuation after these 22 months)).
• ringen for ørerne, øresmerter
• ringing sound in the ears, ear pain
Den gennemsnitlige terminale halveringstid for elimination varierede fra 15 til 16 dage for doseringsgruppen 2 x 500 mg og fra 17 til 21 dage for doseringsgruppen 2 x 1.000 mg.
Mean terminal elimination half-life ranged from 15 to 16 days for the 2 × 500 mg dose group and 17 to 21 days for the 2 × 1000 mg dose group.
Neurologiske bivirkninger
Neurologic disorders
• Recidiveret/ refraktært follikulært lymfom
• Relapsed/refractory follicular lymphoma
+myokardieinfarkt4 og 6, arytmier, +atrieflimren, takykardi, +hjertesygdom
+myocardial infarction4 and 6, arrhythmia, +atrial fibrillation, tachycardia, +cardiac
5 symptomer på kraniel neuropati.
Rarely fatal cases reported 5 signs and symptoms of cranial neuropathy.
Patienter som udvikler svært cytokinfrigivelsessyndrom bør have deres infusion afbrudt omgående (se pkt.
Patients who develop severe cytokine release syndrome should have their infusion interrupted immediately (see section 4.2) and should receive aggressive symptomatic treatment.
Urinvejsinfektion Bronkitis Herpes zoster Nasofaryngitis
Herpes zoster Nasopharyngitis
Patienter med non-Hodgkin-lymfom skal derefter undersøges for tegn på tumorlysesyndrom, inklusive relevante laboratorieundersøgelser.
Patients with non-Hodgkin's lymphoma should then be evaluated for evidence of tumour lysis syndrome including appropriate laboratory tests and, for pulmonary infiltration, with a chest X-ray.
• rastløshed, søvnproblemer
• difficulty sleeping (insomnia)